Testing long-acting HIV injections for people whose virus is controlled

This trial is comparing two versions of long-acting HIV injections: an ultra-long-acting version and a standard long-acting version. Both combinations use medications called cabotegravir and rilpivirine, which work together to keep HIV under control. The study is testing whether the ultra-long-acting version is just as effective and safe as the standard long-acting version, with the goal of giving people treatment options that may require fewer injections.

People with HIV who have their virus well-controlled often want treatment options that are simpler and require fewer visits to the clinic. This medication offers the potential to work longer between doses, which could mean fewer injections per year compared to current options.